Latest On Enochian Biosciences, Inc (ENOB):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-03-13 12:58 EST | News | Enochian BioSciences regains Nasdaq compliance by filing pending reports | N/A |  |
| 2023-02-24 03:36 EST | News | Enochian gets Nasdaq listing deficiency notice for not filing 10-Q | N/A | |
| 2022-12-01 10:06 EST | News | Enochian gets Nasdaq notice for delaying crucial filings | N/A | |
| 2022-10-21 22:42 EST | News | Enochian Biosciences receives non-compliance letter from Nasdaq | N/A | |
| 2022-10-17 14:35 EST | News | Enochian stock climbs on US patent for oncology platform | N/A | |
| 2022-07-01 22:17 EST | News | Enochian BioSciences discovers two sets of altered animal data in two of its studies | N/A | |
| 2022-06-01 14:11 EST | News | Enochian Biosciences plunges after Hindenburg releases full short report | N/A | |
| 2022-05-26 11:10 EST | News | Enochian Biosciences plunges after co-founder arrested in alleged murder-for-hire plot, short call from Hindenburg (updated) | N/A | |
| 2022-05-26 11:10 EST | News | Enochian BioSciences Co-founder Serhat Gumrukçu charged with serious crimes | N/A | |
| 2022-05-25 16:31 EST | News | Enochian Biosciences plunges after co-founder arrested in alleged murder-for-hire plot, short call from Hindenburg | N/A | |
| 2021-10-18 12:20 EST | News | Enochian BioSciences completes Pre-IND process for a potential cure for HIV | N/A | |
| 2021-09-28 15:49 EST | News | Enochian Biosciences drops recording biggest one-day loss in over a year | N/A | |
| 2021-07-21 06:46 EST | News | Enochian Biosciences shares skyrocket after FDA accepts Pre-IND request for HIV treatment | N/A | |
| 2021-07-21 06:46 EST | News | Enochian Biosciences, RAPT Therapeutics leads healthcare gainers; Avenue Therapeutics, Inhibikase Therapeutics among major losers | N/A | |
| 2021-07-21 06:45 EST | News | Enochian shoots 71% on $29M direct offering priced at-the-market | N/A | |
| 2021-07-21 06:39 EST | News | Enochian shares surge on COVID-19 treatment technology license agreement | N/A | |
| 2021-07-21 06:30 EST | News | Enochian Biosciences: A Follow Through For An HIV Cure | N/A | |
| 2021-07-21 06:16 EST | News | Enochian Biosciences shares rise after FDA accepts hepatitis treatment Pre-IND request | N/A | |
| 2021-04-14 07:03 EST | News | Enochian Biosciences: Small Biotech With Ambitious Goals In HIV And HBV | N/A | |
| 2021-03-25 13:03 EST | News | Enochian Bio rallies 29% on case report of complete remission in brain tumor | N/A | |
| 2021-03-14 14:00 EST | News | Enochian Biosciences (ENOB) Presents At H.C. Wainwright Global Life Sciences Conference | N/A | |
| 2021-02-18 07:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-12-06 17:14 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-26 19:52 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-23 23:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-22 17:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-20 19:45 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-19 03:54 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-17 03:53 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 15:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 12:39 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-24 08:50 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 04:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-31 12:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 08:42 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 00:53 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 16:54 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-14 10:32 EST | News | Enochian Biosciences -3.8% on filing to offer shares | N/A | |
| 2020-07-09 08:37 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-26 08:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 04:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-08 19:01 EST | News | Enochian Biosciences up big on advancement of potential HIV cure | N/A | |
| 2020-06-08 19:01 EST | News | CHK, RIG among premarket gainers | N/A | |
| 2020-06-04 19:08 EST | Insider Trade | Rene Sindlev has acquired 20,000 shares indirectly via RS Bio ApS. | Buy | |
| 2020-06-04 19:08 EST | Insider Trade | Rene Sindlev has acquired 40,000 shares indirectly via RS Bio ApS. | Buy | |
| 2020-06-04 19:08 EST | Insider Trade | Rene Sindlev has acquired 31,500 shares indirectly via RS Bio ApS. | Buy | |
| 2020-06-04 19:08 EST | Insider Trade | Luisa Puche has directly acquired 5,000 shares and currently holds 5,000 shares. | Buy | |
| 2020-05-27 04:42 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-17 20:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-15 20:29 EST | Financials | Company financials have been released. | Neutral | |
About Enochian Biosciences, Inc (ENOB):
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-HB-01, a coopting Hepatitis B polymerase; ENOB-DC-01, an off-the-shelf DC vaccine pulsed with MCV lysate; ENOB-DC-11 innovative DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intratumoral injection. The company has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Center, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Enochian Biosciences, Inc. is headquartered in Los Angeles, California.
General
- Name Enochian Biosciences, Inc
- Symbol ENOB
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 10
- Fiscal Year EndJune
- IPO Date2015-02-02
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.enochianbio.com
View More
Valuation
- Price/Book (Most Recent Quarter) 1.13
View More
Financials
- Most Recent Quarter 2020-12-31
- Return on Assets -5%
- Return on Equity -7%
- Earnings Per Share -$0.48
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 172.96 million
- EBITDA -10918323
- Book Value Per Share $3.46
View More
Share Statistics
- Shares Outstanding 46.75 million
- Shares Float 15.7 million
- % Held by Insiders 6863%
- % Held by Institutions 5.16%
- Shares Short 650249
- Shares Short Prior Month 648641
- Short Ratio 3.6
- Short % of Float 10%
- Short % of Shares Outstanding 1%
View More
Technicals
- Beta 0.32
- 52 Week High $4.9
- 52 Week Low $2.08
- 50 Day Moving Average 3.86
- 200 Day Moving Average 3.45
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Enochian Biosciences, Inc (ENOB) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Enochian Biosciences, Inc (ENOB) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2020-12-31 | $N/A | -$0.06 | ||
| 2020-09-30 | 2020-12-31 | $N/A | -$0.06 | ||
| 2020-06-30 | 2020-09-30 | $N/A | -$0.05 | ||
| 2020-03-31 | 2020-06-30 | $N/A | -$0.09 | ||
| 2019-12-31 | 2020-03-31 | $N/A | -$0.03 | ||
| 2019-09-30 | 2019-12-31 | $N/A | -$0.04 | ||
| 2019-06-30 | 2019-09-30 | $N/A | -$0.09 | ||
| 2019-03-31 | 2019-06-30 | $N/A | $0.03 | ||
| 2018-12-31 | 2019-03-31 | $N/A | -$0.07 | ||
| 2018-09-30 | 2018-12-31 | $N/A | -$0.45 | ||
| 2018-06-30 | 2018-09-30 | $N/A | -$0.01 | ||
| 2018-03-31 | 2018-06-30 | $N/A | -$0.06 | ||
| 2017-12-31 | 2018-03-31 | $N/A | -$0.12 | ||
| 2017-09-30 | 2017-12-31 | $N/A | -$0.08 | ||
| 2017-06-30 | 2017-09-30 | $N/A | -$0.02 | ||
| 2017-03-31 | 2017-06-30 | $N/A | -$0.01 | ||
| 2016-12-31 | 2017-03-31 | $N/A | -$0.03 | ||
| 2016-09-30 | 2016-09-30 | $N/A | -$0.08 | ||
| 2016-06-30 | 2016-06-30 | -$0.08 | |||
| 2016-03-31 | 2016-03-31 | $N/A | -$0.02 | ||
| 2015-12-31 | 2015-12-31 | $42525 | -$0.04 | ||
| 2015-09-30 | 2015-09-30 | $N/A | -$0.04 | ||
| 2015-03-31 | 2015-03-31 | $N/A | -$0.13 |
Enochian Biosciences, Inc (ENOB) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Jan 31 2020 |
|---|---|---|---|---|---|
| Research Development | 1.33 million | N/A | N/A | 2.31 million | 2.31 million |
| Income Before Tax | -2.93 million | N/A | N/A | -1.51 million | -1.51 million |
| Selling General Administrative | 1.94 million | N/A | N/A | 1.49 million | 1.49 million |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Ebit | -2.84 million | N/A | N/A | -1.47 million | -1.47 million |
| Operating Income | -3.31 million | N/A | N/A | -3.83 million | -3.83 million |
| Income Tax Expense | -1158 | -122794 | N/A | N/A | N/A |
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Total Other Income Expense Net | N/A | N/A | N/A | 2.31 million | 2.31 million |
| Net Income From Continuing Operations | -2.93 million | N/A | N/A | -1.51 million | -1.51 million |
| Net Income Applicable to Common Shares | -2.93 million | -2.4 million | -4.1 million | N/A | -1.51 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Jan 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | -41694 | N/A | N/A |
| Change to Liabilities | -310501 | 264511 | N/A | -295928 | 19709 |
| Total Cash Flow from Investing Activities | N/A | -10448 | N/A | -41694 | -63705 |
| Net Borrowings | N/A | N/A | N/A | 6.2 million | N/A |
| Total Cash Flow from Financial Activities | N/A | N/A | 6.2 million | N/A | N/A |
| Change to Operating Activities | -119749 | 109249 | N/A | 223244 | -447201 |
| Change in Cash | N/A | N/A | 2.31 million | N/A | -2.51 million |
| Total Cash from Operating Activities | -2.76 million | -2.25 million | -3.84 million | -3.84 million | -2.58 million |
| Depreciation | N/A | N/A | 28186 | N/A | 29245 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | 11698 |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | -35263 | 1.38 million | N/A | -2.29 million | -468194 |
| Capital Expenditures | N/A | N/A | 41694 | N/A | 63705 |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Jan 31 2020 |
|---|---|---|---|---|---|
| Total Liabailities | 10.94 million | N/A | N/A | 10.29 million | N/A |
| Total Stockholder Equity | 161.94 million | N/A | N/A | 170.22 million | N/A |
| Other Current Liabilities | 766513 | N/A | N/A | N/A | 170.22 million |
| Total Assets | 172.89 million | N/A | N/A | 180.51 million | N/A |
| Common Stock | 4676 | 4664 | 4650 | N/A | N/A |
| Other Current Assets | 583028 | N/A | N/A | N/A | 4650 |
| Retained Earnings | -69.52 million | -66.58 million | -64.19 million | -60.09 million | -60.09 million |
| Other Liabilities | 2.07 million | 2.76 million | 3.18 million | N/A | 2.01 million |
| Other Assets | 30484 | 137550 | 137550 | N/A | 137550 |
| Cash | 3.43 million | N/A | N/A | 10.94 million | 10.94 million |
| Total Current Liabilities | 1.56 million | 832177 | N/A | 971271 | 971271 |
| Other Stockholder Equity | -3094 | -13027 | -41416 | N/A | -55745 |
| Property, Plant & Equipment | 735481 | 2.39 million | 2.48 million | N/A | 2.56 million |
| Total Current Assets | 4.01 million | 6.07 million | N/A | 11.27 million | 11.27 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | -4.6 million | -2.31 million | -269062 | N/A | 3.68 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | 5.93 million | N/A | N/A | 5.71 million | 5.71 million |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 792102 | 282376 | N/A | 328366 | 328366 |
Enochian Biosciences, Inc (ENOB) Chart:
Enochian Biosciences, Inc (ENOB) News:
Below you will find a list of latest news for Enochian Biosciences, Inc (ENOB) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Enochian Biosciences, Inc (ENOB) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Latest ENOB Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 52 | $3.46 |
| Jun 13, 2022 7:59 PM EST | 34 | $3.45 |
| Jun 13, 2022 7:59 PM EST | 18 | $3.43 |
| Jun 13, 2022 7:59 PM EST | 53 | $3.45 |
| Jun 13, 2022 7:59 PM EST | 100 | $3.445 |
Enochian Biosciences, Inc (ENOB) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1527728/000173112220000699/0001731122-20-000699-index.htm |
| 2020-02-11 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1527728/000000000020001291/0000000000-20-001291-index.htm |
| 2020-04-10 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1527728/000000000020003118/0000000000-20-003118-index.htm |
| 2020-07-16 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1527728/000000000020006516/0000000000-20-006516-index.htm |
| 2019-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1527728/000173112219000304/0001731122-19-000304-index.htm |
| 2019-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1527728/000173112219000305/0001731122-19-000305-index.htm |
| 2019-06-05 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1527728/000173112219000306/0001731122-19-000306-index.htm |
| 2019-06-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1527728/000173112219000310/0001731122-19-000310-index.htm |
| 2019-06-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1527728/000173112219000353/0001731122-19-000353-index.htm |
| 2019-08-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1527728/000173112219000423/0001731122-19-000423-index.htm |
| 2019-08-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1527728/000173112219000424/0001731122-19-000424-index.htm |
| 2019-08-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1527728/000173112219000425/0001731122-19-000425-index.htm |
| 2019-08-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1527728/000173112219000516/0001731122-19-000516-index.htm |
| 2019-08-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1527728/000173112219000518/0001731122-19-000518-index.htm |
| 2019-08-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1527728/000173112219000520/0001731122-19-000520-index.htm |
| 2019-08-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1527728/000173112219000522/0001731122-19-000522-index.htm |
| 2019-08-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1527728/000173112219000524/0001731122-19-000524-index.htm |
| 2019-09-30 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1527728/000173112219000575/0001731122-19-000575-index.htm |
| 2019-10-28 | 10-K/A | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1527728/000173112219000631/0001731122-19-000631-index.htm |
| 2019-11-01 | PRE 14C | Other preliminary information statements | https://www.sec.gov/Archives/edgar/data/1527728/000173112219000658/0001731122-19-000658-index.htm |
| 2019-11-12 | DEF 14C | Other definitive information statements | https://www.sec.gov/Archives/edgar/data/1527728/000173112219000670/0001731122-19-000670-index.htm |
| 2019-11-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1527728/000173112219000682/0001731122-19-000682-index.htm |
| 2019-11-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1527728/000173112219000687/0001731122-19-000687-index.htm |
| 2019-11-14 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/1527728/000173112219000698/0001731122-19-000698-index.htm |
| 2019-11-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1527728/000173112219000710/0001731122-19-000710-index.htm |
| 2019-11-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1527728/000173112219000737/0001731122-19-000737-index.htm |
| 2019-11-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1527728/000173112219000739/0001731122-19-000739-index.htm |
| 2019-11-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1527728/000173112219000747/0001731122-19-000747-index.htm |
| 2019-12-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1527728/000173112219000774/0001731122-19-000774-index.htm |
| 2020-01-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1527728/000173112220000004/0001731122-20-000004-index.htm |
| 2020-01-09 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1527728/000173112220000030/0001731122-20-000030-index.htm |
| 2020-01-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1527728/000173112220000033/0001731122-20-000033-index.htm |
| 2020-01-10 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1527728/000173112220000035/0001731122-20-000035-index.htm |
| 2020-02-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1527728/000173112220000085/0001731122-20-000085-index.htm |
| 2020-02-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1527728/000173112220000112/0001731122-20-000112-index.htm |
| 2020-02-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1527728/000173112220000199/0001731122-20-000199-index.htm |
| 2020-03-09 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1527728/000173112220000234/0001731122-20-000234-index.htm |
| 2020-03-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1527728/000173112220000335/0001731122-20-000335-index.htm |
| 2020-04-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1527728/000173112220000410/0001731122-20-000410-index.htm |
| 2020-05-11 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1527728/000173112220000479/0001731122-20-000479-index.htm |
| 2020-05-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1527728/000173112220000488/0001731122-20-000488-index.htm |
| 2020-05-22 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1527728/000173112220000559/0001731122-20-000559-index.htm |
| 2020-06-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1527728/000173112220000630/0001731122-20-000630-index.htm |
| 2020-06-12 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1527728/000173112220000644/0001731122-20-000644-index.htm |
| 2020-06-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1527728/000173112220000652/0001731122-20-000652-index.htm |
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1527728/000173112220000662/0001731122-20-000662-index.htm |
| 2020-06-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1527728/000173112220000699/0001731122-20-000699-index.htm |
| 2020-07-13 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1527728/000173112220000725/0001731122-20-000725-index.htm |
| 2020-07-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1527728/000173112220000727/0001731122-20-000727-index.htm |
| 2020-07-16 | S-3/A | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1527728/000173112220000738/0001731122-20-000738-index.htm |
| 2020-07-16 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1527728/000173112220000740/0001731122-20-000740-index.htm |
| 2020-07-20 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1527728/000173112220000750/0001731122-20-000750-index.htm |
| 2020-07-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1527728/000173112220000751/0001731122-20-000751-index.htm |
| 2020-09-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1527728/000173112220000954/0001731122-20-000954-index.htm |
| 2020-09-23 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1527728/000173112220000975/0001731122-20-000975-index.htm |
| 2020-10-28 | 10-K/A | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1527728/000173112220001098/0001731122-20-001098-index.htm |
| 2020-07-20 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1527728/999999999520001867/9999999995-20-001867-index.htm |
Enochian Biosciences, Inc (ENOB) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Enochian Biosciences, Inc (ENOB). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 6863%Institutional Ownership: 516%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-01-07 | Luisa Puche | Chief Financial Officer | Buy | 5,000.00 | 5,000.00 | https://www.sec.gov/Archives/edgar/data/1527728/000173112220000033/0001731122-20-000033-index.htm | ||
| 2019-05-29 | Rene Sindlev | Director | Buy | 20,000.00 | 6.60 | 132,000.00 | 6,504,544.00 | https://www.sec.gov/Archives/edgar/data/1527728/000173112219000304/0001731122-19-000304-index.htm |
| 2019-06-03 | Rene Sindlev | Director | Buy | 40,000.00 | 6.70 | 268,000.00 | 6,544,544.00 | https://www.sec.gov/Archives/edgar/data/1527728/000173112219000305/0001731122-19-000305-index.htm |
| 2019-06-04 | Rene Sindlev | Director | Buy | 31,500.00 | 6.70 | 211,050.00 | 6,576,044.00 | https://www.sec.gov/Archives/edgar/data/1527728/000173112219000310/0001731122-19-000310-index.htm |